Drug Profile


Alternative Names: [S,S]-Reboxetine; PNU-165442G

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Morpholines; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Fibromyalgia; Major depressive disorder; Postherpetic neuralgia; Stress incontinence

Most Recent Events

  • 12 Mar 2014 Efficacy and adverse events data from a phase II trial in Stress incontinence presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008) ,
  • 25 Feb 2009 Discontinued - Phase-II for Diabetic neuropathies in USA, Czech Republic, Finland, Netherlands, South Africa and Spain (PO)
  • 25 Feb 2009 Discontinued - Phase-II for Major depressive disorder in Estonia and Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top